Diabetes Conference-NFOD 2026

Immunotherapy represents a promising frontier in the management of Type 1 diabetes by targeting the autoimmune mechanisms responsible for the destruction of pancreatic beta cells. Current strategies focus on modulating the immune system, preserving residual beta-cell function, and potentially delaying or preventing disease onset in at-risk individuals. Approaches include monoclonal antibodies, antigen-specific vaccines, regulatory T-cell therapies, and combination immune interventions. Early clinical studies have shown encouraging results in reducing autoimmunity, maintaining endogenous insulin production, and improving glycemic stability. Integrating immunotherapy with conventional management, such as insulin therapy and lifestyle interventions, may offer a disease-modifying approach that enhances long-term outcomes and patient quality of life. Continued research in immunotherapeutic strategies holds the potential to shift Type 1 diabetes care from symptom management toward prevention and disease modification.